RecruitingEarly Phase 1NCT06864884

A Phase 1 Study of ARC-001 in Participants Undergoing Third Molar Extraction

A Phase 1 Randomized, Placebo-Controlled, Blinded Study Evaluating the Safety, Tolerability, and Pharmacokinetics of ARC-001 in Participants Undergoing Third Molar Extraction


Sponsor

Arcato Laboratories, Inc.

Enrollment

30 participants

Start Date

Feb 26, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

The study will test the investigational product gel against placebo (which contains no active ingredient) to determine if it is safe after wisdom tooth extraction. The main questions the study will answer are: 1. How much of the investigational product is absorbed in the blood? 2. Are there side effects?


Eligibility

Min Age: 18 YearsMax Age: 55 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called ARC-001 and a drug called Placebo gel for people with acute post operative pain and third molar extraction surgery. The study is currently recruiting participants at 1 location.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGARC-001

Gel formulation containing investigational anesthetic.

DRUGPlacebo gel

Gel that contains no active ingredients.


Locations(1)

CenExel JBR

Salt Lake City, Utah, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06864884


Related Trials